Financial News

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

9.630 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	137
Open	9.630
Bid (Size)	4.560 (4,000)
Ask (Size)	9.960 (100)
Prev. Close	9.630
Today's Range	9.630 - 9.630
52wk Range	6.340 - 76.00
Shares Outstanding	34,422,063
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

March 17, 2026

Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potential

From MiNK Therapeutics

Via GlobeNewswire

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

March 11, 2026

Via Chartmill

Performance

YTD	-13.4%	-13.4%
1 Month	-16.0%	-16.0%
3 Month	-19.4%	-19.4%
6 Month	-29.2%	-29.2%
1 Year	+13.3%	+13.3%

More News

What's going on in today's pre-market session ↗

March 11, 2026

Via Chartmill

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

March 10, 2026

Via Chartmill

Earnings Scheduled For August 14, 2025 ↗

August 14, 2025

Via Benzinga

Why Did INKT Stock Surge 70% In Pre-Market Today? ↗

March 10, 2026

Via Stocktwits

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers

March 10, 2026

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia

February 03, 2026

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease

January 08, 2026

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

November 20, 2025

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics (INKT) Earnings Call Transcript ↗

November 14, 2025

Via The Motley Fool

MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation

November 14, 2025

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics's Earnings Outlook ↗

November 13, 2025

Via Benzinga

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

November 07, 2025

From MiNK Therapeutics

Via GlobeNewswire

Earnings Scheduled For November 14, 2025 ↗

November 14, 2025

Via Benzinga

MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development

November 05, 2025

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

October 30, 2025

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

September 29, 2025

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

September 25, 2025

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

September 18, 2025

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics Extends Cash Runway ↗

August 14, 2025

Via The Motley Fool

MiNK INKT Q2 2025 Earnings Call Transcript ↗

August 14, 2025

Via The Motley Fool

MiNK Therapeutics Inc (NASDAQ:INKT) Reports Wider Q2 2025 Loss, Advances Clinical Pipeline Amid Market Caution ↗

August 14, 2025

Via Chartmill

MiNK Therapeutics Cuts Q2 Cash Use 31% ↗

August 14, 2025

Via The Motley Fool

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

August 14, 2025

From MiNK Therapeutics

Via GlobeNewswire

Frequently Asked Questions

Is MiNK Therapeutics, Inc. - Common Stock publicly traded?

Yes, MiNK Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does MiNK Therapeutics, Inc. - Common Stock trade on?

MiNK Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for MiNK Therapeutics, Inc. - Common Stock?

The ticker symbol for MiNK Therapeutics, Inc. - Common Stock is INKT on the Nasdaq Stock Market

What is the current price of MiNK Therapeutics, Inc. - Common Stock?

The current price of MiNK Therapeutics, Inc. - Common Stock is 9.630

When was MiNK Therapeutics, Inc. - Common Stock last traded?

The last trade of MiNK Therapeutics, Inc. - Common Stock was at 03/26/26 04:00 PM ET

What is the market capitalization of MiNK Therapeutics, Inc. - Common Stock?

The market capitalization of MiNK Therapeutics, Inc. - Common Stock is 331.48M

How many shares of MiNK Therapeutics, Inc. - Common Stock are outstanding?

MiNK Therapeutics, Inc. - Common Stock has 331M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Financial News

MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

Price and Volume

Top News

Performance

More News

Frequently Asked Questions

Popular Pages